Institution
National Cheng Kung University
Education•Tainan City, Taiwan•
About: National Cheng Kung University is a education organization based out in Tainan City, Taiwan. It is known for research contribution in the topics: Population & Thin film. The organization has 49723 authors who have published 69799 publications receiving 1437420 citations. The organization is also known as: NCKU.
Topics: Population, Thin film, Microstructure, Dielectric, Heat transfer
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Transparent conductive ZnO/Ag/ZnO multilayer electrodes having much lower electrical resistance than the widely used transparent electrodes were prepared by simultaneous RF magnetron sputtering of ZnOs and DC magnetron stuttering of Ag as mentioned in this paper.
254 citations
••
TL;DR: It is indicated that VIM-2 and its variant have become the most prevalent metalloenzymes in Pseudomonas in Taiwan.
Abstract: A total of 209 clinical isolates of Pseudomonas (193 Pseudomonas aeruginosa, 10 P. putida, 4 P. stutzeri, and 2 P. fluorescens isolates) with reduced susceptibilities to imipenem and/or ceftazidime were subjected to PCR assays with primers specific for blaIMP-1, blaIMP-2, blaVIM-1, and blaVIM-2 and sequence analysis to identify the metallo-β-lactamases (MBLs) prevalent among these organisms in Taiwan; and 21 isolates gave positive results. Five isolates including two P. putida and three P. stutzeri isolates were found to carry blaIMP-1, and six isolates including five P. putida and one P. stutzeri isolates harbored blaVIM-2. The remaining 10 isolates were P. aeruginosa, and all were found to carry a novel variant of blaVIM-2, designated blaVIM-3. There are only two nucleotide differences between blaVIM-2 and blaVIM-3, leading to two amino acid alterations. Our findings indicate that VIM-2 and its variant have become the most prevalent metalloenzymes in Pseudomonas in Taiwan. Southern hybridization with the blaVIM-2-, blaVIM-3-, and blaIMP-1 -specific probes revealed that only two VIM-2-producing P. putida isolates appeared to carry the MBL gene on plasmids. Pulsed-field gel electrophoresis showed that six VIM-3-producing P. aeruginosa isolates and two IMP-1-producing P. stutzeri isolates were genetically related, suggesting that the spread of these MBL genes in Taiwan could be due to clonal dissemination as well as genetic exchange between different clones.
254 citations
••
TL;DR: The sorption of tetracycline (TC), a common antibiotic, on palygorskite (PFL-1), a fibrous clay mineral of high surface area and high sorptivity towards organic compounds, is conducted, suggesting that palyGorskites could be a good candidate to remove TC from wastewater containing higher amounts of TC.
254 citations
••
TL;DR: A kinetic model was developed to evaluate the metabolism of glucose fermentation of those Clostridium species in the batch cultures and was able to accurately describe the profile of glucose degradation as well as production of biomass, butyrate, acetate, ethanol, and hydrogen observed in thebatch tests.
254 citations
••
TL;DR: The combination of osimertinib and savolitinib has acceptable risk-benefit profile and encouraging antitumour activity in patients with MET-amplified, EGFR mutation-positive, advanced NSCLC, who had disease progression on a previous EGFR TKI.
Abstract: Summary Background Preclinical data suggest that EGFR tyrosine kinase inhibitors (TKIs) plus MET TKIs are a possible treatment for EGFR mutation-positive lung cancers with MET-driven acquired resistance. Phase 1 safety data of savolitinib (also known as AZD6094, HMPL-504, volitinib), a potent, selective MET TKI, plus osimertinib, a third-generation EGFR TKI, have provided recommended doses for study. Here, we report the assessment of osimertinib plus savolitinib in two global expansion cohorts of the TATTON study. Methods In this multi-arm, multicentre, open-label, phase 1b study, we enrolled adult patients (aged ≥18 years) with locally advanced or metastatic, MET-amplified, EGFR mutation-positive non-small-cell lung cancer, who had progressed on EGFR TKIs. We considered two expansion cohorts: parts B and D. Part B consisted of three cohorts of patients: those who had been previously treated with a third-generation EGFR TKI (B1) and those who had not been previously treated with a third-generation EGFR TKI who were either Thr790Met negative (B2) or Thr790Met positive (B3). In part B, patients received oral osimertinib 80 mg and savolitinib 600 mg daily; after a protocol amendment (March 12, 2018), patients who weighed no more than 55 kg received a 300 mg dose of savolitinib. Part D enrolled patients who had not previously received a third-generation EGFR TKI and were Thr790Met negative; these patients received osimertinib 80 mg plus savolitinib 300 mg. Primary endpoints were safety and tolerability, which were assessed in all dosed patients. Secondary endpoints included the proportion of patients who had an objective response per RECIST 1.1 and was assessed in all dosed patients and all patients with centrally confirmed MET amplification. Here, we present an interim analysis with data cutoff on March 29, 2019. This study is registered with ClinicalTrials.gov , NCT02143466 . Findings Between May 26, 2015, and Feb 14, 2019, we enrolled 144 patients into part B and 42 patients into part D. In part B, 138 patients received osimertinib plus savolitinib 600 mg (n=130) or 300 mg (n=8). In part D, 42 patients received osimertinib plus savolitinib 300 mg. 79 (57%) of 138 patients in part B and 16 (38%) of 42 patients in part D had adverse events of grade 3 or worse. 115 (83%) patients in part B and 25 (60%) patients in part D had adverse events possibly related to savolitinib and serious adverse events were reported in 62 (45%) patients in part B and 11 (26%) patients in part D; two adverse events leading to death (acute renal failure and death, cause unknown) were possibly related to treatment in part B. Objective partial responses were observed in 66 (48%; 95% CI 39–56) patients in part B and 23 (64%; 46–79) in part D. Interpretation The combination of osimertinib and savolitinib has acceptable risk–benefit profile and encouraging antitumour activity in patients with MET-amplified, EGFR mutation-positive, advanced NSCLC, who had disease progression on a previous EGFR TKI. This combination might be a potential treatment option for patients with MET-driven resistance to EGFR TKIs. Funding AstraZeneca.
254 citations
Authors
Showing all 49872 results
Name | H-index | Papers | Citations |
---|---|---|---|
Yi Chen | 217 | 4342 | 293080 |
Yang Yang | 164 | 2704 | 144071 |
R. E. Hughes | 154 | 1312 | 110970 |
Mercouri G. Kanatzidis | 152 | 1854 | 113022 |
Thomas J. Smith | 140 | 1775 | 113919 |
Hui Li | 135 | 2982 | 105903 |
Gerald M. Reaven | 133 | 799 | 80351 |
Chi-Huey Wong | 129 | 1220 | 66349 |
Joseph P. Vacanti | 119 | 441 | 50739 |
Kai Nan An | 109 | 953 | 51638 |
Ding-Shinn Chen | 104 | 774 | 46068 |
James D. Neaton | 101 | 331 | 64719 |
David C. Christiani | 100 | 1052 | 55399 |
Jo Shu Chang | 99 | 639 | 37487 |
Yu Shyr | 98 | 542 | 39527 |